Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial.

Howard I. Scher(Memorial Sloan Kettering Cancer Center), Robert Dreicer(University of Virginia), David B. MacLean(Takeda (United States)), Niels Borgstein(Ironwood Pharmaceuticals (United States)), Iain J. Webb(Takeda (United States)), Bindu Tejura(Takeda (United States)), Connie Lee(University of Michigan), Karim Fizazi(Université de Lille)
Journal of Clinical Oncology
May 20, 2014
10.1200/jco.2014.32.15_suppl.5014
Cited by 1

Related Papers

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k